HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
Phase 3positiveORPATHYSTAGRISSOPositive
AI Analysis
Summary
HUTCHMED announced that ORPATHYS plus TAGRISSO achieved statistically significant improvements in progression-free and overall survival in a Phase III trial for MET-driven EGFR-mutated lung cancer progressing on TAGRISSO monotherapy. This represents the first global Phase III trial to demonstrate such benefits in this treatment setting.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Statistically significant and clinically meaningful improvements in progression-free survival and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Importance:8/10
Sentiment:
0.85
Phase 3lung cancerEGFR-mutatedsurvival benefitcombination therapy
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 17, 2026 12:00 AM